Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 11/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PDXK | O00764 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745527 | 0.83 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPKAPK2HPGDHSD17B10 | |
| SCHEMBL21193052 | 0.83 | KDM4E (0.47) | ALDH1A1KDM4EMAPKAPK2HPGDHSD17B10 | |
| SCHEMBL30784909 | 0.83 | KDM4E (0.47) | ALDH1A1KDM4EMAPKAPK2HPGDHSD17B10 | |
| SCHEMBL25346557 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MAPKAPK2 | |
| SCHEMBL23694612 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MAPKAPK2 | |
| SCHEMBL5230567 | 0.78 | MAPKAPK2 (0.40) | ALDH1A1MAPKAPK2 | |
| SCHEMBL23214000 | 0.75 | MAPKAPK2 (0.34) | ALDH1A1KDM4EMAPKAPK2 | |
| SCHEMBL20189957 | 0.75 | MAPKAPK2 (0.35) | ALDH1A1KDM4EMAPKAPK2 | |
| SCHEMBL31134680 | 0.75 | MAPKAPK2 (0.51) | MAPKAPK2 | |
| SCHEMBL20189316 | 0.75 | MAPKAPK2 (0.51) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4476213-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119072474-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-114630822-B | Biaryl dihydroorotate acid dehydrogenase inhibitors | 詹森生物科技公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4041714-B1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023151575-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4041714-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114630822-A | Biaryl dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021070132-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | ALDH1A1 54/4885KDM4E 1665/4885MAPKAPK2 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.